Executive Summary

Florida’s mental health law, commonly referred to as the Baker Act, gives the state the power to detain individuals for up to 72 hours of involuntary psychiatric examination. What happens to those individuals once the door to a Baker Act Receiving Facility (BARF) closes is a question that existing law answers with troubling vagueness, that existing federal audits answer with damning evidence, and that a landmark 2026 peer-reviewed study answers with specificity that should alarm every Florida policymaker and patient rights advocate.

The finding is stark: in U.S. state psychiatric hospitals where patients are involuntarily committed, nearly two-thirds are prescribed antipsychotic medications at the maximum recommended dose or above it, and more than 40% are prescribed two or more antipsychotic drugs simultaneously — a practice called antipsychotic polypharmacy — despite best-practice guidelines recommending monotherapy. These prescribing patterns exist without a single standardized program to monitor the health outcomes associated with them. Some of the patients receiving these drugs have not consented to them. And under Florida law, the formal protections that should constrain this practice are routinely outpaced by clinical reality.

This report argues; on the basis of peer-reviewed clinical research, federal audit findings, Florida statutes, U.S. Supreme Court precedent, and international evidence, that involuntary psychiatric drug prescribing in Florida operates in a legal and clinical accountability gap, that the medications being administered without consent carry documented risks that are disproportionately borne by the most vulnerable populations, and that the legislative reforms already proven to reduce unnecessary Baker Act detentions can and must be extended to protect the medication rights of those who are detained.

The evidence points toward one conclusion that is consistent with every legislative reform Florida has enacted since 2021: voluntary, fully informed consent and alternative services produce better outcomes, and fewer drugs administered to captive patients, than any system built on coercion.

Section 1: The Legal Architecture — What Florida Law Says About Medication Consent

Florida’s Baker Act embeds a formal commitment to patient rights that is often honored in statute and ignored in practice. The Act’s legislative declaration, codified in Florida Statute Chapter 394, states that persons with mental illnesses are entitled to “individual dignity, express and informed consent, and humane and skillful treatment.” These are not aspirational principles, they are the stated legal foundation of every Baker Act intervention.

The Consent Framework on Paper

Under the Baker Act, a patient undergoing involuntary examination retains the legal right to refuse medication unless a court determines otherwise. Florida Statute § 394.4625 requires that patients be offered voluntary status and that transfers to involuntary placement trigger specific procedural protections. When a voluntary patient; or an authorized person on their behalf, requests discharge, that request must be communicated to a physician within 12 hours.

For children, Florida law is even more explicit. Under Florida Statute § 39.407, psychotropic medications may not be administered to a child in state custody without a court authorization supported by a physician’s signed medical report detailing: the diagnosed condition, the specific drug and dosage range, the expected benefits, the recognized side effects and risks, and a review of alternative treatments. The court must receive that motion within 3 working days of the prescription being issued. Minors, under Florida’s Baker Act FAQ guidance, cannot consent to psychotropic medication in an inpatient setting; only a parent, legal guardian, or court-appointed guardian advocate can authorize it.

The Gap Between Statute and Reality

The gap between what the law requires and what facilities actually do is documented, in federal audit findings, in investigative journalism, and in the clinical literature, to be substantial.

A 2023 federal audit by the U.S. Department of Health and Human Services Office of Inspector General examined 115 records of Florida foster children prescribed psychotropic medications. The findings were severe: psychotropic medications prescribed for 36 children were not recorded in the state’s primary case management system; medication logs were missing from 66% of case files; and authorization records (the court-ordered documentation required by § 39.407) were not found in more than one-third of files reviewed. For opioid medications prescribed to 60 children in the sample, documentation was absent in 57 of 60 cases.

For foster children over age 13 in Florida, more than one in three are prescribed psychotropic medications, a rate that dwarfs the general population rate of approximately 6%. The federal audit found that the state was systematically failing to follow its own statutory requirements to document, authorize, and monitor those prescriptions. Authorization records, the legal protection intended to ensure a court reviews whether a child’s involuntary medication is appropriate, were missing in more than one-third of cases.

The legal framework exists. The enforcement does not.

Section 2: The Clinical Reality — What Involuntary Prescribing Looks Like Inside Facilities

The First U.S. Study of Its Kind

In January 2026, the first peer-reviewed study to examine antipsychotic prescribing patterns in a U.S. state psychiatric hospital was published in Frontiers in Psychiatry. The setting was San Antonio State Hospital in Texas; a facility that, like Florida’s BARFs, predominantly houses patients on involuntary commitments.

The findings established a benchmark that every Florida policymaker and patient advocate should measure the state’s own facilities against:

• Nearly two-thirds (65%) of patients were prescribed antipsychotics at or above the maximum recommended dose; 35.8% at the maximum, and 29.2% above it.
• 8% were prescribed two simultaneous scheduled antipsychotics (antipsychotic polypharmacy, or APP); 6.1% were prescribed three.
• 5% were prescribed a long-acting injectable antipsychotic (LAIA), a formulation used specifically because it removes the patient’s ability to stop taking the drug by missing a pill.
• Patients were prescribed an average of three scheduled psychotropic medications in total.
• The median length of stay was 3 years; meaning these high-dose, multi-drug regimens were being maintained not for days or weeks, but for years, in patients who never consented to them.

The study’s author was explicit about why these findings matter: “State hospitals involuntarily commit patients with serious mental illness to receive treatment with antipsychotic medications, which are associated with a multitude of dose-dependent adverse effects.” She noted that no standardized programs exist to monitor health outcomes associated with these prescribing patterns.

Antipsychotic Polypharmacy: Outside Guidelines, Inside Locked Wards

Antipsychotic polypharmacy (prescribing two or more antipsychotic drugs simultaneously) is explicitly discouraged by clinical best-practice guidelines, including those of the American Psychiatric Association. A separate national study of 86,034 patients discharged from U.S. state psychiatric inpatient hospitals found a polypharmacy prevalence of 12% overall; rising to 18% among patients who received any antipsychotic, with schizophrenia diagnosis and lengths of stay of 90 days or more as the strongest predictors. The 2025 data from Australia’s Victorian hospital network found the disparity even more sharply: 82% of involuntary patients received high-dose antipsychotics, compared to 17% of voluntary patients. In this study, the difference between involuntary and voluntary patients is so large that there’s only about a 1 in 1,000 chance it happened by accident. In other words, involuntary patients really are being put on much higher doses; it’s not just a fluke in the data. The involuntary status of a patient is, itself, a predictor of receiving more aggressive, higher-dose, multi-drug prescribing.

What These Drugs Do to the Body

Antipsychotics carry documented, serious adverse effects that are dose-dependent; meaning the higher the dose, the higher the risk. These include:

• Metabolic syndrome: Weight gain, increased blood cholesterol, increased risk of Type 2 diabetes
• Cardiovascular effects: Cardiac muscle problems, increased stroke risk in older adults
• Neurological effects: Tardive dyskinesia (involuntary, often permanent repetitive movements), extrapyramidal symptoms (involuntary muscle spasms, tremors, rigidity)
• Sedation: Drowsiness significant enough to impair basic functioning, memory, and attention
• Increased mortality risk in older adults with dementia-related psychosis, an FDA black box warning

For children and adolescents in involuntary settings, the risks are particularly acute. A systematic review of psychotropic safety data from 337,686 children and teens found that common adverse effects from antipsychotics included drowsiness, abnormal muscle movements, and significant weight gain. The study acknowledged “limited data about adverse events for many of these medications,” meaning prescribers are administering drugs to children in locked wards whose full risk profiles are not fully characterized by the medical literature.

Antidepressant drugs also come with the FDA’s suicidality black box warning which is not a minor footnote, it is the strongest warning the agency can place on a drug label. In pooled analyses of 24 clinical trials, the FDA found that antidepressants increase the risk of suicidal thinking and behavior in children, adolescents, and young adults up to age 24, enough that every prescription antidepressant now carries a boxed warning about suicidality in people under 25. For youth and young adults, that warning means antidepressant‑treated patients had more suicidal thoughts and behaviors than those on placebo, especially in the first weeks of treatment. This is the FDA’s own data and language, and it cannot be responsibly dismissed or waved off as “just paperwork.”

Section 3: The Legal Case — What the Constitution and Supreme Court Require

The legal framework governing involuntary psychiatric medication extends well beyond Florida’s Baker Act and reaches the U.S. Constitution itself.

The Supreme Court’s Four-Part Test

In Sell v. United States, 539 U.S. 166 (2003), the U.S. Supreme Court established that an individual has a constitutionally protected “interest in avoiding involuntary administration of antipsychotic drugs”, an interest that only an “essential” or “overriding” state interest can overcome. Building on Washington v. Harper and Riggins v. Nevada, the Court held that forced medication of a mentally ill patient requires a four-part analysis:

1. An important government interest must be at stake
2. There must be a substantial probability that the medication will enable treatment without causing side effects that undermine the patient’s ability to function
3. Involuntary medication must be the least intrusive treatment available; courts must first consider alternative, non-drug approaches
4. The administration of the drugs must be medically appropriate and, in the patient’s, best medical interest

The Court emphasized that this framework will allow forced medication “only in rare instances.” It requires case-by-case judicial scrutiny, not blanket facility authority. It requires that less intrusive alternatives be considered and ruled out. It requires that the specific medication proposed be in the patient’s best interest.

What the 2026 state hospital study reveals is a system in which two-thirds of involuntarily committed patients are prescribed maximum or above-maximum doses, 42% are on polypharmacy, and there are no standardized programs to monitor whether any of these prescriptions meet the Sell criteria of being medically appropriate, minimally intrusive, and beneficial to the individual patient.

Florida’s Own Standards: “Least Restrictive” and “Informed Consent”

Florida Statute § 394’s own legislative declaration requires that persons with mental illnesses receive treatment in the least restrictive setting appropriate and that they be offered services that address the cause of the crisis; not merely suppress its symptoms. The Baker Act’s consent requirements are explicit: voluntary patients who request discharge must be processed within 12 hours; involuntary status requires active clinical judgment, not administrative default.

These are not obscure regulatory requirements. They are the legal foundation upon which every Baker Act receiving facility is authorized to operate. The federal audit evidence (missing authorization records, absent medication logs, undocumented prescriptions) establishes that Florida is systematically failing to enforce those requirements for its most vulnerable patients: children in state custody.

Section 4: The Human Cost — Patients and Families Speak

“More Sedated Than Stabilized”

A 2025 scoping review published in the Journal of Mental Health synthesized findings from 21 qualitative studies examining individuals’ subjective experiences of forced psychiatric medication. The themes that emerged were consistent and devastating:

• Participants described emotional blunting , a chemically induced flattening of affect that they experienced not as symptom relief but as the erasure of their personality
• Long-term consequences included fear, a perceived erosion of identity, and a lasting sense of having been violated by the medical system they were compelled to enter
• Participants reported that the experience of forced medication damaged their willingness to seek future mental health care, replicating the same pattern documented for involuntary hospitalization: coercive intervention trains people to avoid the system

This mirrors what research on involuntary hospitalization has established directly: a 2021 qualitative study found that 70% of young people who had experienced involuntary psychiatric hospitalization reported negative impacts on their ability to trust others, most frequently mental health providers. Almost half reported learning to conceal symptoms from providers out of fear of being detained again. Three-quarters said the experience made them unwilling to disclose suicidal feelings, even when they continued to feel suicidal after discharge. Forced medication, administered within the same coercive system, intensifies those outcomes.

Children Bear a Disproportionate Burden

Florida’s foster children; a population disproportionately Black, disproportionately trauma-exposed, and disproportionately subjected to Baker Act examinations, are being prescribed psychotropic medications at rates more than 2.8 times higher than children in the general population. The authorization systems designed to protect them are failing. The monitoring systems designed to catch adverse effects are absent.

A 2025 national investigation found that states across the country — including Florida — continue to fail to rein in psychotropic prescribing for foster youth, despite years of damning federal audits and the existence of statutory oversight requirements. The report described children who were “all I did was sleep”; sedated to manageability on drug regimens that were never properly authorized, never properly monitored, and never connected to a therapeutic plan.

Racial Disparities in Involuntary Prescribing

Research has consistently found that Black patients are prescribed higher doses of antipsychotics than White patients; and are more likely to be prescribed long-acting injectable formulations, which are specifically used for patients considered too unwell to consent to oral medication. A 2025 University College London analysis found that among patients prescribed antipsychotics for severe mental illness, Black patients tended to receive the highest doses, while White patients received the lowest, with patients from deprived areas also prescribed higher doses on average.

In Florida, where Black children account for 32% of school Baker Act examinations despite making up 20% of the relevant student population, these racial prescribing disparities are not a hypothetical concern. They are the predictable downstream consequence of a system that already subjects Black children to coercive intervention at disproportionate rates and then exposes them to more aggressive drug prescribing once they are inside.

Section 5: Legislative Reforms That Have Already Proven What Is Possible

The same pattern documented in CCHR QUARTERLY REPORT: Evidence That Coercive Psychiatric Detention Fails and Harms Those It Purports to Help (that targeted legislative intervention rapidly and measurably reduces the harms of the coercive Baker Act system) applies with equal force to the question of involuntary medication. The reforms that have been enacted, and those that remain to be enacted, follow a consistent logic: restore consent, require clinical judgment, and fund alternatives.

HB 7021 (2024): The Groundwork Has Been Laid

House Bill 7021, signed into law by Governor DeSantis in June 2024, enacted the most significant overhaul of the Baker Act in 53 years. Its provisions directly relevant to involuntary medication include:

• Changing law enforcement’s obligation from “shall” to “may” initiate involuntary examination — reducing the pipeline of patients flowing into Baker Act facilities in the first place, and by extension the population exposed to involuntary prescribing
• Creating the Children’s Behavioral Health Ombudsman — an accountability mechanism that can investigate complaints from children and families about their treatment inside Baker Act facilities, including complaints about involuntary medication practices

Since HB 7021 took effect on July 1, 2024, Florida has maintained a 20% overall decline in Baker Act commitments and a 17% decline in juvenile commitments, with the state now below 158,000 involuntary examinations annually down from a pre-pandemic high of 210,000. Every patient who does not enter a Baker Act receiving facility is a patient who is not exposed to involuntary prescribing.

The reform impact over the past five years illustrates a clear relationship between legislative action and outcomes:

What each of these reforms has in common: They reduced the number of people entering involuntary psychiatric custody. They restored decision-making authority to patients, parents, and communities. They did not improve outcomes by giving facilities more authority to prescribe; they improved outcomes by reducing the number of people subjected to involuntary treatment in the first place.

Section 6: What Actually Works — Voluntary, Lifestyle‑Based Alternatives

The international evidence base for voluntary, lifestyle‑based approaches to mental health is substantial, and it demonstrates that many of the outcomes Florida’s Baker Act system claims to pursue can be achieved through exercise and nutrition, without coercive drug prescribing.

Exercise: Comparable Benefits to Therapy and Medication

Multiple large reviews and meta‑analyses now show that structured physical activity produces moderate, clinically meaningful reductions in depressive symptoms, often comparable to psychotherapy and, in some trials, similar to antidepressant medication.

Key findings include:

• A 2026 Cochrane review concluded that exercise has a moderate benefit on depression compared with no treatment or control, and that its effects are similar to psychological therapy; comparisons with antidepressants also suggested similar benefit, though evidence there was lower‑certainty.
• Meta‑analyses of randomized trials found that people assigned to exercise had significantly lower depression scores than controls, with effect sizes in the “moderate” range; resistance training alone produced a mean effect size of about 0.66, meaning a clear reduction in symptoms.
• In psychosis and schizophrenia, at least 90 minutes per week of moderate‑to‑vigorous exercise has been associated with improvements in total symptoms, positive symptoms, negative symptoms, social problems, and aggressive behaviors again without any coercive medication.

These outcomes are not marginal. They show that for many people, regular movement; walking, mixed exercise programs, resistance training, can deliver symptom relief on par with standard clinical treatments, while also improving physical health and autonomy.

Nutrition: Whole‑Diet Interventions Reduce Depressive Symptoms

Dietary interventions targeting overall eating patterns, not just single supplements, have also demonstrated measurable reductions in depression. Randomized controlled trials and meta‑analyses show that shifting from ultra‑processed, high‑sugar diets toward whole grains, fruits, vegetables, legumes, nuts, and healthy fats has significant mental health effects.

Key evidence:

• A 2019 meta‑analysis of 16 randomized trials involving over 45,000 people found that dietary improvement significantly reduced depressive symptoms, with a small‑to‑moderate effect size; benefits were particularly strong in women.
• The landmark SMILES trial, the first study to test diet as a primary treatment for major depression, found that about one‑third of participants in the dietary intervention group achieved remission of major depression after 12 weeks, compared with only 8% in the social‑support control group.
• A thesis‑level meta‑analysis of whole‑diet interventions reported a large reduction in depressive symptoms, showing that comprehensive dietary changes can have powerful mood effects when properly supported.

Taken together, this evidence shows that food is not incidental to mental health — it is a modifiable, voluntary factor that can substantially improve depressive symptoms without any psychiatric drugs.

Lifestyle Guidance for Severe Mental Illness

European Psychiatric Association guidance on lifestyle interventions in severe mental illness specifically recommends integrating physical activity, dietary change, and sleep regularity into care for adults with schizophrenia, bipolar disorder, and related conditions, because these interventions improve both mental symptoms and physical health risk factors. For people who have been repeatedly Baker Acted, these lifestyle tools offer a way to regain agency over their own recovery, rather than remaining dependent on involuntary admissions and high‑dose drug regimens.

The core principle is the opposite of involuntary psychiatric prescribing: supporting the person in building daily habits (movement, nourishing food, regular sleep) that they choose and control. The effectiveness of exercise and nutrition rests on the premise that people in crisis, given information, support, and respect, can and do participate meaningfully in their own recovery, and that this participation is itself therapeutically essential.

Psychiatric Advance Directives: Giving Patients Their Voice Before the Crisis

Psychiatric Advance Directives (PADs), legal documents completed by individuals at a time of wellness to document their treatment preferences for future psychiatric crises, offer a proven mechanism for respecting medication autonomy even when a person loses capacity to express it in the moment. A PAD allows a person to specify:

• Which medications they refuse under any circumstances
• Which treatment facilities they prefer or want to avoid
• Who is authorized to speak for them

Florida’s current Baker Act framework does not systematically require facilities to check for or honor psychiatric advance directives before initiating medication. A straightforward legislative reform, requiring Baker Act receiving facilities to screen for and document the existence of a PAD before initiating any psychotropic medication, would close this gap without changing the clinical authority of treating physicians in genuine emergencies.

Section 7: The Accountability Gap and the Path to Reform

The 2026 state hospital study made one finding that is, in some ways, more alarming than the prescribing statistics themselves: there are currently no standardized programs in U.S. state psychiatric hospitals to monitor the health outcomes associated with the antipsychotic prescribing patterns documented there. Not in Texas. Not in Florida. Not in any state.

The same absence characterizes Florida’s treatment of involuntarily committed patients more broadly. HB 7021 funded data collection on Baker Act admissions and outcomes, a reform CCHR Florida supported precisely because accountability requires transparency. But that data collection framework does not yet include medication-specific outcome monitoring: which drugs are being prescribed at which doses, to patients who declined consent, with what documented clinical rationale, and with what documented health outcomes.

Specific Reforms That Follow From the Evidence

The evidence reviewed in this report supports the following specific, actionable legislative and regulatory reforms:

1. Mandatory Antipsychotic Stewardship Programs in Baker Act Receiving Facilities
   Require all Baker Act designated Receiving Facilities to implement Antipsychotic Stewardship Programs; standardized processes for tracking antipsychotic prescribing patterns, documenting clinical rationale for high-dose or polypharmacy decisions, and monitoring and reporting health outcomes associated with involuntary medication. This mirrors the recommendation of the 2026 peer-reviewed study and extends the data transparency framework established by HB 7021. This must also include “informed consent” which isn’t just a signature; it’s a rights‑based process where patients, parents and guardians are fully informed of risks, alternatives, and the non‑medical nature of psychiatric diagnosis, and are free to say no to the proposed drugs.
2. Mandatory Psychiatric Advance Directive Screening Before Medication
   Require Baker Act facilities to screen all incoming patients for the existence of a psychiatric advance directive and document the results of that screening before initiating any psychotropic medication. Where a PAD exists, it must be reviewed by the treating physician and departures from its directives must be documented and reported.
3. Enforcement of Existing § 39.407 Authorization Requirements
   The federal audit evidence is clear: Florida is not enforcing its own statutory authorization requirements for psychotropic medications prescribed to children in state custody. The Legislature should require DCF to audit medication authorization compliance across all Baker Act facilities treating minors and publicly report findings annually, with facility-level accountability for non-compliance including the suspension or revocation of designation as a Baker Act Receiving Facility.
4. Racial Disparity Reporting in Drug Prescribing
   Require Baker Act receiving facilities to report medication prescribing data; including antipsychotic dose, polypharmacy rates, and long-acting injectable prescribing rates, disaggregated by race and ethnicity, as part of the BADCS data collection framework established under HB 7021.

Section 8: The Ethical and Legal Case

The Sell framework is not a technicality. It reflects a constitutional principle that a civilized society recognized more than two decades ago: forcing a person to accept a drug that alters their brain and their sense of self is among the most serious intrusions the state can make on an individual’s bodily autonomy. It requires the highest justification, the least restrictive alternative, and — above all — the documented absence of any other way to serve the state’s interest.

Florida’s Baker Act Receiving Facilities are not currently operating under that standard. They are operating under a system in which involuntary commitment automatically creates clinical authority to prescribe, in which that authority is not systematically monitored for compliance with best-practice guidelines or statutory protections, and in which the most vulnerable patients (children, foster youth, Black and minority patients) bear the greatest burden of the most aggressive prescribing patterns.

A September 2025 Washington University survey found that only 40% of Americans support forced psychiatric medication; making it the least-supported mental health policy measured, less popular than involuntary hospitalization, and dramatically less popular than voluntary community-based care, which commanded bipartisan support above 70%. The public, across party lines, does not believe that locking a person in a facility and forcing them to take drugs is appropriate healthcare. The research agrees with them. The constitutional framework agrees with them. The legislative history of the reforms that have already succeeded in Florida agrees with them.

Recommendations

Based on the evidence in this report, CCHR Florida calls for:

1. Antipsychotic Stewardship Programs mandated at all Florida Baker Act designated Receiving Facilities, with annual public reporting of prescribing patterns, dosing levels, polypharmacy rates, and documented health outcomes associated with involuntary medication orders. This must also include “informed consent” which isn’t just a signature; it’s a rights‑based process where patients, parents and guardians are fully informed of risks, alternatives, and the non‑medical nature of psychiatric diagnosis, and are free to say no to the proposed drugs
2. Psychiatric Advance Directive screening required before initiation of any psychotropic medication in a Baker Act setting, with documented compliance as a condition of facility designation and failure to do so would result in the suspension or revocation of designation as a Baker Act Receiving Facility if already designated as such
3. Full enforcement audit of Florida § 39.407 authorization requirements for psychotropic medications prescribed to children in state custody, with results published publicly and facility-level accountability for non-compliance including the suspension or revocation of designation as a Baker Act Receiving Facility.
4. Disaggregated medication data, including antipsychotic dose, polypharmacy rates, and long-acting injectable rates by race, ethnicity, age, and admission type incorporated into the DCF Baker Act Data Collection System (BADCS) and Baker Act Dashboard
5. Legislative requirement that every Baker Act Receiving Facility document compliance with the Sell constitutional standard before initiating psychotropic medication over a patient’s objection, with legal penalties for non-compliant facilities receiving state Medicaid contracts and including the suspension or revocation of designation as a Baker Act Receiving Facility

Methodology

This report is based on: peer-reviewed clinical research indexed in PubMed and Frontiers in Psychiatry; federal audit reports published by the U.S. Department of Health and Human Services Office of Inspector General; U.S. Supreme Court opinions and associated legal analysis; Florida statutes and legislative analyses from the Florida Senate and House of Representatives; data from the DCF Baker Act Dashboard and USF Baker Act Reporting Center; investigative journalism from the Tampa Bay Times, Reason Magazine, and the Imprint; public survey research from Washington University in St. Louis; and international clinical evidence from the Open Dialogue literature. All Florida legislative data reflects enrolled bills and Governor’s actions through June 2026.

CCHR Florida is a non-profit mental health watchdog established to investigate and expose psychiatric violations of human rights. The Citizens Commission on Human Rights was co-founded in 1969 by the Church of Scientology and Dr. Thomas Szasz, Professor of Psychiatry Emeritus, State University of New York Health Science Center.